Telomere and telomerase as targets for anti-cancer and regeneration therapies

Acta Pharmacologica Sinica

Volumn 26, Issue 5, 2005, Pages 513-518

  Hsu, Yi Hsin ^a   Lin, Jing Jer ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cancer; Gene therapy; Regenerative disease; Telomerase; Telomere

Indexed keywords

ANTINEOPLASTIC AGENT; RIBONUCLEOPROTEIN; SMALL MOLECULE TRANSPORT AGENT; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ANTINEOPLASTIC ACTIVITY; CELL DEATH; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL REGENERATION; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE THERAPY; HUMAN; HUMAN CELL; PROTEIN DNA INTERACTION; REVIEW; SOMATIC CELL; TARGET CELL; TELOMERE;

DNA-BINDING PROTEINS; ENZYME INHIBITORS; GENE THERAPY; HUMANS; NEOPLASMS; RNA, MESSENGER; TELOMERASE; TELOMERE;

EID: 18744386160     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2005.00098.x     Document Type: Review

References (80)

1. Zakian VA. Telomeres: beginning to understand the end. Science 1995; 270: 1601-7.
2. Olovnikov AM. A theory of marginotomy. The incomplete copying of template margin in enzymatic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol 1973; 41: 181-90.
3. Watson JD. Origin of concatemeric DNA. Nature (New Biol) 1972; 239: 197-201.
4. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345: 458-60.
5. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989; 59: 521-9.
6. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-5.
7. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787-91.
8. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004; 23: 2919-33.
9. Gisselsson D, Jonson T, Petersen A, Strombeck B, Dal Cin P, Hoglund M, et al. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc Natl Acad Sci USA 2001; 98: 12683-8.
10. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279: 349-52.
11. Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres in mammalian cells. Oncogene 2002; 21: 598-610.
12. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell 2002; 2: 257-65.
13. Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T, et al. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res 2001; 61: 3053-61.
14. Blackburn EH. Switching and signaling at the telomere. Cell 2001; 106: 661-73.
15. Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 1998; 16: 3323-30.
16. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, et al. Inhibition of telomerase limits the growth of human cancer cells. Nature Med 1999; 5: 1164-70.
17. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 1999; 13: 2388-99.
18. Bodnar AG, Kim NW, Effros RB, Chiu CP. Mechanism of telomerase induction during T cell activation. Exp Cell Res 1996; 228: 58-64.
19. Masutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, Metz GB, et al. Telomerase maintains telomere structure in normal human cells. Cell 2003; 114: 241-53.
20. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al. The RNA component of human telomerase. Science 1995; 269: 1236-41.
21. Herbert BS, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 1999; 96: 14276-81.
22. Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Wan X, Niwa K, et al. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res 1998; 58: 5406-10.
23. Rezler EM, Beam DJ, Hurley LH. Telomeres and telomerases as drug targets. Curr Opin Pharmacol 2002; 2: 415-23.
24. Neidle S, Parkinson G. Telomere maintenance as a target for anticancer drug discovery. Nat Rev Drug Discov 2002; 1: 383-93.
25. Pascole E, Wenz C, Lingner J, Hauel N, Priepke H, Kauffmann I, et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem 2002; 277: 15566-72.
26. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 2001; 20: 6958-68.
27. Chang CC, Kuo IC, Lin JJ. A novel carbazole derivative, BMVC: a potential antitumor agent and fluorescence marker of cancer cells. Chem Biodivers 2004; 1: 1377-84.
28. Read M, Harrison RJ, Romagnoli B, Tanious FA, Gowan SH, Reszka AP. Structure-based design of selective and potent G-quadruplex-mediated telomerase inhibitors. Proc Natl Acad Sci USA 2001; 98: 4844-9.
29. Sen D, Gilbert W. The structure of telomeric DNA: DNA quardruplex formation. Curr Opin Struct Biol 1991; 1: 435-8.
30. Chang CC, Kuo IC, Ling IF, Chen CT, Chen HC, Lou PJ. Detection of quadruplex DNA structures in human telomeres by a fluorescent carbazole derivative. Anal Chem 2004; 76: 4490-4.
31. Siddiqui-Jain A, Grand CL, Bearss DJ, Hurley LH. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci USA 2004; 99: 11593-8.
32. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, et al. Mammalian telomeres end in large duplex loop. Cell 1999; 97: 503-14.
33. Zahler AM, Williamson JR, Cech TR, Prescott DM. Inhibition of telomerase by G-quartet DNA structure. Nature 1991; 350: 718-20.
34. Wheelhouse RT, Sun D, Han H, Han FX, Hurley LH. Cationic porphyrins as telomerase inhibitors: the interaction of tetra-(N-methyl-4-pyridyl)porphine with quadruplex DNA. J Am Chem Soc 1998; 120: 3261-2.
35. Heald RA, Modi C, Cookson JC, Hutchinson I, Laughton CA, Gowan SM, et al. Antitumor polycyclic acridines. 8. Synthesis and telomerase-inhibitory activity of methylated pentacyclic acridinium salts. J Med Chem 2002; 45: 590-7.
36. Sun D, Thompson B, Cathers BE, Salazar M, Kerwin SM, Trent JO, et al. Inhibition of human telomerase by a G-quadruple-interactive compound. J Med Chem 1997; 40: 2113-28.
37. Riou JF, Guittat L, Mailliet P, Laoui A, Renou E, Petitgenet O, et al. Cell senesscence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc Natl Acad Sci USA 2002; 99: 2672-7.
38. Perry PJ, Read MA, Davies RT, Gowan SM, Reszka AP, Wood AA, et al. 2,7-Disubstituted amidofluorenone derivatives as inhibitors of human telomerase. J Med Chem 1999; 42: 2679-84.
39. Cairns D, Michalitsi E, Jenkins TC, Mackay SP. Molecular modeling and cytotoxicity of substituted anthraquinones as inhibitors of human telomerase. Bioorgan Med Chem 2002; 10: 803-7.
40. Chang CC, Wu JY, Chang TC. A carbazole derivative synthesis for stabilizing the quadruplex structure. J Chin Chem Soc 2003; 50: 185-8.
41. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997; 277: 955-9.
42. Ducrest AL, Szutorisz H, Lingner J, Nabholz M. Regulation of the human telomerase reverse transcriptase gene. Oncogene 2002; 21: 541-52.
43. Ulaner GA, Hu JF, Vu TH, Oruganti H, Giudice LC, Hoffman AR. Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium. Int J Cancer 2000; 85: 330-5.
44. Yi X, White DM, Aisner DL, Baur JA, Wright WE, Shay JW. An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia 2000; 2: 433-40.
45. Ku WC, Cheng AJ, Wang TCV. Inhibition of telomerase activity by PKC inhibitors on human nasopharyngeal cancer cells in culture. Biochem Biophys Res Commun 1997; 241: 730-6.
46. Li H, Zhao LL, Funder JW, Liu JP. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J Biol Chem 1997; 272: 16729-32.
47. Li H, Zhao L, Yang Z, Funder JW, Liu JP. Telomerase is controlled by protein kinase Ca in human breast cancer cells. J Biol Chem 1998; 273: 33436-42.
48. Kang SS, Kwon T, Kwon DY, Do SI. Akt protein kinase enhances human telomerase activity through phosphorylation of telo-merase reverse transcriptase subunit. J Biol Chem 1999; 274: 13085-90.
49. Wong JMY, Kusdra L, Collins K. Subnuclear shuttling of human telomerase induced by transformation and DNA damage. Nature Cell Biol 2002; 4: 731-6.
50. Pendino F, Flexor M, Delhommeau F, Buet D, Lanotte M, Segal-Bendirdjian E. Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation. Proc Natl Acad Sci USA 2001; 98: 6662-7.
51. Mano Y, Shimizu T, Tanuma S, Takeda K. Synergistic downregulation of telomerase activity and hTERT mRNA expression by combination of retinoic acid and GM-CSF in human myeloblastic leukemia ML-1 cells. Anticancer Res 2000; 20: 1649-52.
52. Huang HS, Chiou JF, Fong Y, Hou CC, Lu YC, Wang JY, et al. Activation of human telomerase reverse transcriptase expression by some new symmetrical bis-substituted derivatives of the anthraquinone. J Med Chem 2003; 46: 3300-7.
53. Rudolph KL, Chang S, Millard M, Schreiber-Agus N, DePinho RA. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000; 287: 1253-8.
54. Wyllie FS, Jones CJ, Skinner JW, Haughton MF, Wallis C, Wynford-Thomas D, et al. Telomerase prevents the accelerated cell ageing of Werner syndrome fibroblasts. Nat Genet 2000; 24: 16-7.
55. Shi S, Gronthos S, Chen S, Reddi A, Counter CM, Robey PG, et al. Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. Nat Biotechnol 2002; 20: 587-91.
56. Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI, et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 2002; 20: 592-6.
57. Counter CM, Meyerson M, Eaton EN, Ellisen ZW, Caddle SD, Haber DA, et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998; 16: 1217-22.
58. Serakinci N, Guldberg P, Burns JS, Abdallah B, Schrodder H, Jensen T, et al. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene 2004; 23: 5095-8.
59. Jiang XR, Jimenez G, Chang E, Kaur KJ, Yan Y, Wilson KS, et al. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat Genet 1999; 21: 111-4.
60. Morales CP, Holt SE, Ouellette M, Kaur KJ, Yan Y, Wilson KS, et al. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet 1999; 21: 115-8.
61. Gonzalez-Suarez E, Samper E, Ramirez A, Flores JM, Martin-Caballero J, Jorcano JL, et al. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J 2001; 20: 2619-30.
62. Artandi SE, Alson S, Tietze MK, Sharpless NE, Yes, Greenberg RA, et al. Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci USA 2002; 99: 8191-6.
63. Devereux TR, Horikawa I, Anna CH, Annab LA, Afshari CA, Barrett JC, et al. DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res 1999; 59: 6087-90.
64. Dessain SK, Yu H, Reddel RR, Beijersbergen RL, Weinberg RA. Methylation of the human telomerase gene CpG island. Cancer Res 2000; 60: 537-41.
65. Cong YS, Bacchetti S. Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J Biol Chem 2000; 275: 35665-8.
66. Takakura M, Kyo S, Sowa Y, Wang Z, Yatabe N, Maida Y, et al. Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res 2001; 29: 3006-11.
67. Misiti S, Nanni S, Fontemaggi G, Cong YS, Wen J, Hirte HW, et al. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol Cell Biol 2000; 20: 3764-71.
68. Kyo S, Takakura M, Kanaya T, Cong YS, Wen J, Hirte HW, et al. Estrogen activates telomerase. Cancer Res 1999; 59: 5917-21.
69. Wang Z, Kyo S, Takakura M, Tanaka M, Yatabe N, Maida Y, et al. Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway. Cancer Res 2000; 60: 5376-81.
70. Won J, Chang S, Oh S, Kim TK. Small-molecule-based identification of dynamic assembly of E2F-pocket protein-histone deacetylase complex for telomerase regulation in human cells. Proc Natl Acad Sci USA 2004; 101: 11328-33.
71. Nakamura M, Kyo S, Kanaya T, Yatabe N, Maida Y, Tanaka M, et al. hTERT-promoter-based tumor-specific expression of MCP-1 effectively sensitizes cervical cancer cells to a low dose of cisplatin. Cancer Gene Ther 2004; 11: 1-7.
72. Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA, et al. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 2000; 60: 5359-64.
73. Komata T, Kondo Y, Kanzawa T, Hirohata S, Koga S, Sumiyoshi H, et al. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 2001; 61: 5796-802.
74. Koga S, Hirohata S, Kondo Y, Komata T, Takakura M, Inoue M, et al. A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 2000; 11: 1397-406.
75. Abdul-Ghani R, Ohana P, Matouk I, Ayesh S, Ayesh B, Laster M, et al. Use of a transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther 2000; 2: 539-44.
76. Sawada T, Yamada O, Yoshimuta N, Hatori K, Fuchinoue S, Teraoka S, et al. Xenoantigen, an aGal epitope-expression construct driven by the hTERT-promoter, specifically kills human pancreatic cancer cell line. Cancer Cell Int 2002; 2: 14-20.
77. Majumdar AS, Hughes DE, Lichtsteiner SP, Wang Z, Lebkowski JS, Vasserot AP, et al. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther 2001; 8: 568-78.
78. Song JS, Kim HP, Yoon WS, Lee KW, Kim MH, Kim KT, et al. Adenovirus-mediated suicide gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter induced apoptosis of ovarian cancer cell line. Biosci Biotechnol Biochem 2003; 67: 2344-50.
79. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10: 673-9.
80. Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002; 21: 674-9.